Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | EZH1 | Q92800 | 2/20 | 0.52 |
| ▸ | EED | O75530 | 1/20 | 0.52 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.52 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.52 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.52 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592733 | 0.89 | EZH2 (0.58) | EZH2HDAC1HDAC6EEDSUZ12 | |
| SCHEMBL12180763 | 0.88 | EZH2 (0.68) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL14816656 | 0.87 | EZH2 (0.55) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL2588061 | 0.86 | EZH2 (0.62) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL2592252 | 0.86 | EZH2 (0.58) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL14716515 | 0.86 | EZH2 (0.64) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL2594806 | 0.84 | EZH2 (0.75) | EZH2HDAC1HDAC6EZH1EED | |
| SCHEMBL2588565 | 0.84 | EZH2 (0.60) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL14733312 | 0.83 | EZH2 (0.56) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL2590359 | 0.82 | EZH2 (0.78) | EZH2HDAC1HDAC6EZH1EED |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | claimed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | claimed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | claimed |
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-8846935-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2013067300-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566328-A1 | INDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | EZH2 1599/4885HDAC1 101/4885HDAC6 212/4885 |
| US-20140350013-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | EZH2 1599/4885HDAC1 101/4885HDAC6 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.